Congenital erythropoietic porphyria: A single-observer clinical study of 29 cases

British Journal of Dermatology

Volumn 167, Issue 4, 2012, Pages 901-913

  Katugampola, R P ^a   Badminton, M N ^b   Finlay, A Y ^a   Whatley, S ^b   Woolf, J ^b   Mason, N ^b   Deybach, J C ^c,d   Puy, H ^c,d   Ged, C ^e   De Verneuil, H ^e   Hanneken, S ^f   Minder, E ^g   Schneider Yin, X ^g   Anstey, A V ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^c CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^d HÔPITAL LOUIS MOURIER   (France)

^e UNIVERSITÉ DE BORDEAUX   (France)

^f UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^g Institute of Laboratory Medicine   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONGENITAL ERYTHROPOIETIC PORPHYRIA; FEMALE; FRANCE; GENOTYPE PHENOTYPE CORRELATION; GERMANY; HEMATOLOGIC DISEASE; HUMAN; MALE; ONSET AGE; PAPULE; PHOTOSENSITIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; SCHOOL CHILD; SWITZERLAND; UNITED KINGDOM;

ADOLESCENT; ADULT; CHILD; COHORT STUDIES; EUROPE; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MIDDLE AGED; PORPHYRIA, ERYTHROPOIETIC; QUALITY OF LIFE; UROPORPHYRINOGEN III SYNTHETASE; YOUNG ADULT;

EID: 84867028256     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.11160.x     Document Type: Article

References (42)

1. Anderson K, Sassa S, Bishop D, et al. Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. In: The Metabolic & Molecular Basis of Inherited Disease (, Scriver CR, Beasdet AL, Sly WS, Valle D, eds), 8th edn. New York: McGraw-Hill Publishing, 2001; 2991-3062.
2. Desnick RJ, Astrin KH,. Congenital erythropoietic porphyria: advances in pathogenesis and treatment. Br J Haematol 2002; 117: 779-95.
3. De Verneuil H, Ged C, Moreau-Gaudry F,. Congenital erythropoietic porphyria. In: The Porphyrin Handbook (, Kadish K, Smith K, Guilard R, eds), 2nd edn. New York: Elsevier Science (U.S.A.), 2003; 43-65.
4. Astrin KH, Warner CA, Yoo HW, et al. Regional assignment of the human uroporphyrinogen III synthase (UROS) gene to chromosome 10q25.2->q26.3. Hum Genet 1991; 87: 18-22.
5. Aizencang G, Solis C, Bishop D, et al. Human uroporphyrinogen-III synthase: genomic organization, alternative promoters and erythroid-specific expression. Genomics 2000; 70: 223-31.
6. Ged C, Moreau-Gaudry F, Richard E, et al. Congenital erythropoietic porphyria: mutation update and correlation between genotype and phenotype. Cell Mol Biol (Noisy-le-Grand) 2009; 55: 53-60.
7. Daïkha-Dahmane F, Dommergues M, Narcy F, et al. Congenital erythropoietic porphyria: prenatal diagnosis and autopsy findings in two sibling fetuses. Pediatr Dev Pathol 2001; 4: 180-4.
8. Verstraeten L, Van Regemorter N, Pardou A, et al. Biochemical diagnosis of a fatal case of Günther's disease in a newborn with hydrops foetalis. Eur J Clin Chem Clin Biochem 1993; 31: 121-8.
9. Fritsch C, Bolsen K, Ruzicka T, et al. Congenital erythropoietic porphyria. J Am Acad Dermatol 1997; 36: 594-610.
10. Katugampola RP,. Assessment of clinical and laboratory data to inform management decisions in congenital erythropoietic porphyria. MD thesis, Cardiff University, U.K., 2010.
11. Katugampola RP, Lake A,. The role of photography in dermatology research. J Vis Commun Med 2012; 35: 5-10.
12. Finlay AY, Khan G,. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-16.
13. Lewis-Jones M, Finlay A,. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol 1995; 132: 942-9.
14. Krabbe P, Weijnen T,. Guidelines for analysing and reporting EQ-5D outcomes. In: The Measurement and Valuation of Health Status Using EQ-5D: A European Perspective (, Brooks R, Rabin R, Decharro F, eds). Dordrecht/Boston/London: Kluwer Academic Publishers, 2003.
15. Basra M, Sue-Ho R, Finlay AY,. The Family Dermatology Life Quality Index: measuring the secondary impact of skin disease. Br J Dermatol 2007; 156: 528-38.
16. Phillips J, Steensma D, Pulsipher M, et al. Congenital erythropoietic porphyria due to a mutation in GATA-1: the first trans-acting mutation causative for a human porphyria. Blood 2007; 109: 2618-21.
17. Katugampola RP, Anstey AV, Finlay AY, et al. A management algorithm for congenital erythropoietic porphyria derived from a study of 29 cases. Br J Dermatol 2012; in press. DOI: 10.1111/j.1365-2133.2012.11154.x
18. Hallai N, Anstey A, Mendelsohn S, et al. Pregnancy in a patient with congenital erythropoietic porphyria. N Engl J Med 2007; 357: 622-3.
19. Hongbo Y, Thomas C, Harrison M, et al. Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? J Invest Dermatol 2005; 125: 659-64.
20. Waters A, Sandhu D, Beattie P, et al. Severity stratification of Children's Dermatology Life Quality Index (CDLQI) scores. Br J Dermatol 2010; 163 (Suppl. 1): 121.
21. UK National Statistics. Available at: http://www.statistics.gov.uk (last accessed 23 July 2012).
22. Pandhi D, Suman M, Khurana N, et al. Congenital erythropoietic porphyria complicated by squamous cell carcinoma. Pediatr Dermatol 2003; 20: 498-501.
23. Herrera S, Moruno T,. Congenital erythropoietic porphyria affecting two brothers. Br J Dermatol 1999; 141: 547-50.
24. Piomelli S, Poh-Fitzpatrick M, Seaman C, et al. Complete suppression of the symptoms of congenital erythropoietic porphyria by long-term treatment with high-level transfusions. N Engl J Med 1986; 314: 1029-31.
25. Levesque M, Legmann P, Le Cloirec A, et al. Radiological features in congenital erythropoietic porphyria (Gunther's disease): report of 3 cases. Pediatr Radiol 1988; 18: 62-6.
26. Holme S, Anstey A, Badminton M, et al. Serum 25-hydroxyvitamin D in erythropoietic protoporphyria. Br J Dermatol 2008; 159: 211-13.
27. Singh DK, Rai R,. Congenital erythropoietic porphyria. Indian Pediatr 2008; 45: 865-6.
28. Soylu A, Kavukçu S, Türkmen M,. Phototherapy sequela in a child with congenital erythropoietic porphyria. Eur J Pediatr 1999; 158: 526-7.
29. De Verneuil H, Moreau-Gaudry F, Ged C, et al. Congenital erythropoietic porphyria. Apropos of a fatal case in the neonatal period due to acute hemolysis with hepatic failure. Arch Pediatr 1995; 2: 755-61.
30. Fritsch C, Land K, Bolsen K, et al. Congenital erythropoietic porphyria. Skin Pharmacol Appl Skin Physiol 1998; 11: 347-57.
31. Bhutani L, Deshpande S, Bedi T, et al. Cyclophosphamide and congenital erythropoietic porphyria. Photodermatology 1985; 2: 394-8.
32. Lange B, Hofweber K, Waldherr R, et al. Congenital erythropoietic porphyria associated with nephrotic syndrome and renal siderosis. Acta Paediatr 1995; 84: 1325-8.
33. Holme SA, Anstey AV, Finlay AY, et al. Erythropoietic protoporphyria in the U.K.: clinical features and effect on quality of life. Br J Dermatol 2006; 155: 574-81.
34. Jong CT, Finlay AY, Pearse AD, et al. The quality of life of 790 patients with photodermatoses. Br J Dermatol 2008; 159: 192-7.
35. Herd R, Tidman M, Ruta D, et al. Measure of quality of life in atopic dermatitis: correlation and validation of two different methods. Br J Dermatol 1997; 136: 502-7.
36. Freesemann A, Gross U, Bensidhoum M, et al. Immunological, enzymatic and biochemical studies of uroporphyrinogen III-synthase deficiency in 20 patients with congenital erythropoietic porphyria. Eur J Biochem 1998; 257: 149-53.
37. Ged C, Mégarbané H, Chouery E, et al. Congenital erythropoietic porphyria: report of a novel mutation with absence of clinical manifestations in a homozygous mutant sibling. J Invest Dermatol 2004; 123: 589-91.
38. To-Figueras J, Badenas C, Mascaró J, et al. Study of the genotype-phenotype relationship in four cases of congenital erythropoietic porphyria. Blood Cells Mol Dis 2007; 38: 242-6.
39. To-Figueras J, Ducamp S, Clayton J, et al. ALAS2 acts as a modifier gene in patients with congenital erythropoietic porphyria. Blood 2011; 118: 1443-51.
40. Solis C, Aizencang G, Astrin KH, et al. Uroporphyrinogen III synthase erythroid promoter mutations in adjacent GATA1 and CP2 elements cause congenital erythropoietic porphyria. J Clin Invest 2001; 107: 753-62.
41. Shady A, Colby B, Cunha L, et al. Congenital erythropoietic porphyria: identification and expression of eight novel mutations in the uroporphyrinogen III synthase gene. Br J Haematol 2002; 117: 980-7.
42. Tezcan I, Xu W, Gurgey M, et al. Congenital erythropoietic porphyria successfully treated by allogeneic bone marrow transplantation. Blood 1998; 92: 4053-8.